IP Library Granted Patent US 8,927,516
Granted Patent B2
US 8,927,516 · App. 13/836,414 · Granted Jan 6, 2015

Combination of DNA repair inhibition with bendamustine or gemcitabine in the treatment of cancer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,927,516
App. No.
13/836,414
Granted
Jan 6, 2015
Kind
B2
Abstract

The invention provides methods for enhancing the cytotoxicity of DNA damage in cancer cells that express thymine DNA glycosylase, and treating tumors accordingly. The methods comprise inhibiting the expression or biologic activity of thymine DNA glycosylase, and inducing DNA damage in the cancer cells. DNA damage may be induced by administration of bendamustine or gemcitabine to the cancer cells.

Claims (8)

1. A method for treating a tumor that expresses thymine DNA glycosylase, comprising transforming cells in the tumor with an inhibitory RNA molecule comprising the nucleic acid sequence of SEQ ID NO: 2, and inducing DNA damage in the cells.

2. The method of claim 1 , wherein inducing DNA damage in the cells comprises irradiating the cells at a radiation dose sufficient to induce DNA damage in the cells.

3. The method of claim 1 , wherein inducing DNA damage in the cells comprises contacting the cells with an agent that damages DNA in an amount effective to induce DNA damage in the cells.

4. The method of claim 3 , wherein the agent that induces DNA damage comprises gemcitabine, bendamustine, or a combination of gemcitabine and bendamustine.

5. The method of claim 1 , wherein the tumor is a tumor of the pancreas, tumor of the lung, tumor of the head and neck, tumor of the kidney, tumor of the hematopoietic system, tumor of the breast, tumor of the ovary, tumor of the colon, tumor of the lymph nodes, tumor of the bladder, tumor of the prostate gland, tumor of the stomach, or a tumor of the esophagus.

6. The method of claim 1 , wherein the method is carried out in vivo.

7. The method of claim 1 , wherein DNA damage is at a level sufficient to induce sustained S phase arrest in the cells.

8. The method of claim 4 , wherein the cells are contacted with an amount of gemcitabine, bendamustine, or a combination of gemcitabine and bendamustine effective to induce DNA damage sufficient to induce sustained S phase arrest in the cells.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2020
From: THE FOX CHASE CANCER CENTER FOUNDATION
To: THE INSTITUTE FOR CANCER RESEARCH
Reel/Frame 053562/0938 →
CONFIRMATORY LICENSE Recorded Mar 17, 2015
From: FOX CHASE CANCER CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035219/0334 →